Suppr超能文献

利用靶标突变稳定化从 DNA 编码化学库中发现蛋白酶激活受体 2 的激动剂和拮抗剂。

Agonists and Antagonists of Protease-Activated Receptor 2 Discovered within a DNA-Encoded Chemical Library Using Mutational Stabilization of the Target.

机构信息

1 Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca R&D, Waltham, MA, USA.

2 Heptares Therapeutics Ltd., Welwyn Garden City, Hertfordshire, UK.

出版信息

SLAS Discov. 2018 Jun;23(5):429-436. doi: 10.1177/2472555217749847. Epub 2018 Jan 9.

Abstract

The discovery of ligands via affinity-mediated selection of DNA-encoded chemical libraries is driven by the quality and concentration of the protein target. G-protein-coupled receptors (GPCRs) and other membrane-bound targets can be difficult to isolate in their functional state and at high concentrations, and therefore have been challenging for affinity-mediated selection. Here, we report a successful selection campaign against protease-activated receptor 2 (PAR2). Using a thermo-stabilized mutant of PAR2, we conducted affinity selection using our >100-billion-compound DNA-encoded library. We observed a number of putative ligands enriched upon selection, and subsequent cellular profiling revealed these ligands to comprise both agonists and antagonists. The agonist series shared structural similarity with known agonists. The antagonists were shown to bind in a novel allosteric binding site on the PAR2 protein. This report serves to demonstrate that cell-free affinity selection against GPCRs can be achieved with mutant stabilized protein targets.

摘要

通过亲和介导的 DNA 编码化学文库筛选发现配体,这取决于蛋白质靶标的质量和浓度。G 蛋白偶联受体 (GPCR) 和其他膜结合靶标难以在其功能状态和高浓度下分离,因此对亲和介导的选择具有挑战性。在这里,我们报告了针对蛋白酶激活受体 2 (PAR2) 的成功筛选活动。我们使用 PAR2 的热稳定突变体,使用我们超过 1000 亿化合物的 DNA 编码文库进行亲和选择。我们观察到在选择过程中富集了一些假定的配体,随后的细胞分析表明这些配体包括激动剂和拮抗剂。激动剂系列与已知激动剂具有结构相似性。拮抗剂被证明结合在 PAR2 蛋白的新变构结合位点上。本报告证明了可以使用稳定的突变蛋白靶标实现针对 GPCR 的无细胞亲和选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验